表紙
市場調查報告書

焦點市場分析:腫瘤崩壞症候群(TLS)

Market Spotlight: Tumor Lysis Syndrome (TLS)

出版商 Datamonitor Healthcare 商品編碼 939985
出版日期 內容資訊 英文 28 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:腫瘤崩壞症候群(TLS) Market Spotlight: Tumor Lysis Syndrome (TLS)
出版日期: 2020年07月24日內容資訊: 英文 28 Pages
簡介

本報告提供全球腫瘤崩壞症候群(TLS)治療市場調查,彙整疾病的背景·概要,主要的治療方法,主要的開發平台藥物概要,主要的已上市藥物趨勢,授權·資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等資料。

目錄

概要

重要點

疾病的背景

治療

  • 預防和監測
  • 擴大體積
  • 醫療療法
  • 腎替代療法

流行病學

  • 發生率的假設

成藥

成功的概率

本源專利

商機

臨床試驗情勢

  • 各狀態贊助商
  • 不同階段贊助商

參考文獻

  • 處方箋資訊

附錄

目錄
Product Code: DMKC0183487

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma).

The number of incident cases is forecast to increase to 13,600 by 2026. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.

The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 61.4%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TLS have been in the late phases of development, with 67% of trials in Phase III-IV, and 33% in Phase II.

The US leads in terms of the number of TLS clinical trials globally, while Italy and Spain lead the major European markets. Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with eight in total.

Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Prophylaxis and monitoring
  • Volume expansion
  • Medical therapies
  • Renal replacement therapy

EPIDEMIOLOGY

  • Incidence assumptions

MARKETED DRUGS

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017-26
  • Figure 2: Probability of success in the TLS pipeline23 Figure 3: Clinical trials in TLS
  • Figure 4: Top 10 drugs for clinical trials in TLS
  • Figure 5: Top 10 companies for clinical trials in TLS
  • Figure 6: Trial locations in TLS
  • Figure 7: TLS trials status
  • Figure 8: TLS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of TLS in selected high-risk malignancies, 2017-26
  • Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
  • Table 3: Incident cases of TLS in acute myeloid leukemia, 2017-26
  • Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
  • Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017-26
  • Table 6: Incidence of Burkitt's lymphoma, and proportion of individuals with TLS, 2017
  • Table 7: Incident cases of TLS in Burkitt's lymphoma, 2017-26
  • Table 8: Marketed drugs for TLS
  • Table 9: Historical global sales, by drug ($m), 2015-19
  • Table 10: Forecasted global sales, by drug ($m), 2020-24